First-in-Human Phase I Study of ALK202, a Novel EGFR/c-MET Bispecific Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

ALK-202 - Allink Biotherapeutics

F. Zhou1; C. Zhou1; C. Lemech2; F. Lou3; A. Spira4; Q. Dang5; W. Jiang6; Z. Li7; J. Park8; L. Wu9; Y. Du10

Jul 31, 2026